论文部分内容阅读
本文报告了663例住院病人之血清CEA及36例胸水CEA放射免疫测定结果。476例肺、胃、肠道、肝、食道癌肿之血清CEA阳性率分别为64.29％、47.27％、40.63％、33.33％、31.48％;187例良性病人(食道除外),假阳性率分别为4.76％、11.96％、7.7％、26.47％;36例胸水中有17例肺癌患者,阳性率为94.12％;17例良性病变中无1例假阳性。结果认为测定胸水CEA水平对鉴别肺良、恶性疾病有其独特的临床价值。血清CEA水平不能独立地作为某些肿瘤的诊断依据。但鉴别原发与继发肝癌、肿瘤的术后随访以及对慢性萎缩性胃炎患者进行动态观察尚有一定意义。
This article reports the results of serum CEA and 36 cases of pleural fluid CEA radioimmunoassay in 663 inpatients. The positive rates of serum CEA in 476 cases of lung, stomach, intestine, liver and esophageal cancer were 64.29%, 47.27%, 40.63%, 33.33%, and 31.48%, respectively; 187 benign patients (excluding esophagus) had false positive rates. 4.76%, 11.96%, 7.7%, 26.47%; 36 cases of lung cancer in 17 patients with lung cancer, the positive rate was 94.12%; 17 cases of benign lesions without false positive. The results suggest that determining CEA levels in pleural effusions has unique clinical value in distinguishing between benign and malignant lung diseases. Serum CEA levels cannot be used independently as a basis for the diagnosis of certain tumors. However, the follow-up of patients with primary and secondary liver cancers and tumors as well as the dynamic observation of patients with chronic atrophic gastritis still have some significance.